X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (199) 199
index medicus (197) 197
infectious diseases (173) 173
hiv infections - drug therapy (170) 170
darunavir/ritonavir (125) 125
female (119) 119
male (119) 119
darunavir (117) 117
pharmacology & pharmacy (115) 115
efficacy (110) 110
adult (108) 108
hiv (102) 102
middle aged (93) 93
safety (91) 91
immunology (86) 86
hiv infections - virology (79) 79
antiretroviral therapy (78) 78
protease inhibitors (75) 75
ritonavir (73) 73
viral load (68) 68
treatment outcome (67) 67
microbiology (63) 63
once-daily darunavir/ritonavir (62) 62
hiv protease inhibitors - therapeutic use (61) 61
hiv-1-infected patients (61) 61
virology (59) 59
darunavir-ritonavir (58) 58
ritonavir - therapeutic use (58) 58
anti-hiv agents - therapeutic use (56) 56
drug therapy, combination (56) 56
hiv-1 - drug effects (54) 54
anti-hiv agents - administration & dosage (52) 52
ritonavir - administration & dosage (51) 51
treatment-naive (50) 50
hiv infection (49) 49
lopinavir/ritonavir (47) 47
aids/hiv (46) 46
hiv-infected patients (46) 46
pharmacokinetics (44) 44
lopinavir (41) 41
antiretroviral drugs (40) 40
drug therapy (40) 40
sulfonamides - therapeutic use (40) 40
antiviral agents (39) 39
double-blind (39) 39
human immunodeficiency virus--hiv (39) 39
hiv-1 (38) 38
therapy (38) 38
cd4 lymphocyte count (37) 37
raltegravir (37) 37
sulfonamides - administration & dosage (37) 37
treatment-experienced patients (37) 37
young adult (36) 36
darunavir/ritonavir monotherapy (35) 35
hiv protease inhibitors - adverse effects (35) 35
ritonavir - adverse effects (35) 35
anti-hiv agents - adverse effects (34) 34
drug resistance, viral (34) 34
hiv protease inhibitors - administration & dosage (34) 34
protease inhibitor (34) 34
naive hiv-1-infected patients (31) 31
drug administration schedule (28) 28
highly active antiretroviral therapy (28) 28
aged (27) 27
hiv-1 - isolation & purification (27) 27
placebo-controlled trial (27) 27
tmc125 etravirine (27) 27
adolescent (26) 26
antiretroviral therapy, highly active - methods (26) 26
active antiretroviral therapy (25) 25
atazanavir (25) 25
dosage and administration (25) 25
rna, viral - blood (25) 25
sulfonamides - adverse effects (25) 25
clinical trials (24) 24
proteases (24) 24
aids (23) 23
analysis (23) 23
reverse-transcriptase inhibitors (23) 23
anti-hiv agents - pharmacokinetics (22) 22
drug interactions (22) 22
efavirenz (22) 22
experienced hiv-1-infected patients (22) 22
hiv-1 - genetics (22) 22
infected patients (22) 22
infection (22) 22
open-label (22) 22
rna (22) 22
drug-resistance (21) 21
hiv protease inhibitors - pharmacology (21) 21
research (21) 21
resistance (21) 21
ritonavir - pharmacokinetics (21) 21
tenofovir (21) 21
antiretroviral therapy, highly active (20) 20
combination (20) 20
darunavir - therapeutic use (20) 20
etravirine (20) 20
hiv infections - immunology (20) 20
hiv patients (20) 20
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


LANCET INFECTIOUS DISEASES, ISSN 1473-3099, 07/2014, Volume 14, Issue 7, pp. 572 - 580
Background Daily oral triple therapy is effective at halting HIV disease progression, but can have toxic effects and is costly. We investigated whether dual... 
INFECTIOUS DISEASES | RALTEGRAVIR | EFFICACY | SAFETY | ANALOGS | EFAVIRENZ | LOPINAVIR/RITONAVIR | DARUNAVIR/RITONAVIR | DOLUTEGRAVIR | SPARING REGIMEN | TENOFOVIR/EMTRICITABINE
Journal Article
PLOS ONE, ISSN 1932-6203, 08/2018, Volume 13, Issue 8
Objective The head-to-head AIDS Clinical Trial Group (ACTG) 5257 clinical trial found raltegravir (RAL) to be superior to atazanavir + ritonavir (ATV/r) and... 
EFFICACY | ERA | MULTIDISCIPLINARY SCIENCES | DARUNAVIR/RITONAVIR | INHIBITORS | HEALTH
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 10/2019, Volume 74, Issue 10, pp. 3030 - 3034
Abstract Background The gold standard for HIV-1 treatment is to administer triple antiretroviral therapy, but a shift to simplified regimens is being explored.... 
INFECTIOUS DISEASES | REVERSE-TRANSCRIPTASE INHIBITORS | EFFICACY | DARUNAVIR/RITONAVIR MONOTHERAPY | RISK | MICROBIOLOGY | PHARMACOLOGY & PHARMACY
Journal Article
MEDICINA CLINICA, ISSN 0025-7753, 08/2018, Volume 151, Issue 3, pp. 128 - 129
Journal Article
AIDS, ISSN 0269-9370, 11/2011, Volume 25, Issue 17, pp. 2113 - 2122
Objective: To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients. Design: Phase IIb, single-arm,... 
INFECTIOUS DISEASES | SAFETY | antiretroviral therapy | nucleoside sparing | raltegravir | INITIAL TREATMENT | IMMUNOLOGY | COMBINATION | VIROLOGY | HIV-1 VIRAL LOAD | ANTIRETROVIRAL DRUG-RESISTANCE | darunavir | LOPINAVIR/RITONAVIR | INFECTION | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 05/2016, Volume 2016, Issue Issue 1, pp. 1589 - 1603
Andrea Antinori,1 Paola Meraviglia,2 Antonella d'Arminio Monforte,3,4 Antonella Castagna,5,6 Cristina Mussini,7 Teresa Bini,4 Nicola Gianotti,5 Stefano... 
darunavir/ritonavir | observational | safety | durability | efficacy
Journal Article
Journal Article
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, ISSN 0305-7453, 07/2017, Volume 72, Issue 7, pp. 2055 - 2059
Objectives: The AtLaS-M randomized trial showed that in patients with HIV-1 RNA < 50 copies/mL on atazanavir/ritonavir + two NRTIs, switching to a dual therapy... 
SUPPRESSIVE ANTIRETROVIRAL THERAPY | PREDICTS | INFECTIOUS DISEASES | IMPACT | SAFETY | DARUNAVIR/RITONAVIR MONOTHERAPY | TREATMENT SIMPLIFICATION | DYNAMICS | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTED PATIENTS
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 11/2019, Volume 74, Issue 11, pp. 3305 - 3314
Abstract Objectives We assessed virological outcomes of darunavir use in France from 2012 to 2016, in three groups of people living with HIV (PLHIV): (i)... 
INFECTIOUS DISEASES | EFFICACY | SAFETY | PROTEASE INHIBITOR MONOTHERAPY | MICROBIOLOGY | OPEN-LABEL | DARUNAVIR/RITONAVIR | NAIVE | HIV-INFECTED PATIENTS | MAINTENANCE | THERAPY | PHARMACOLOGY & PHARMACY | RITONAVIR
Journal Article
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, ISSN 0066-4804, 06/2019, Volume 63, Issue 6
We generated two novel nonpeptidic HIV-1 protease inhibitors (PIs), GRL-001-15 and GRL-003-15, which contain unique crown-like tetrahydropyranofuran (Crn-THF)... 
HIV-1 | DIMERIZATION INHIBITION | EFFICACY | SAFETY | antiretroviral therapy | AIDS | MICROBIOLOGY | DARUNAVIR/RITONAVIR | DOLUTEGRAVIR | DARUNAVIR-RITONAVIR | REPLICATION | protease inhibitors | PHARMACOLOGY & PHARMACY | INFECTION | LIFE EXPECTANCY
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 01/2019, Volume 74, Issue 1, pp. 149 - 156
Abstract Background Dolutegravir combined with darunavir/cobicistat is a promising NRTI-sparing and/or salvage strategy for the treatment of HIV-1 infection.... 
INFECTIOUS DISEASES | RITONAVIR-BOOSTED DARUNAVIR | RALTEGRAVIR | SAFETY | ELVITEGRAVIR | COBICISTAT | MICROBIOLOGY | DARUNAVIR/RITONAVIR | RILPIVIRINE DUAL THERAPY | PROTEASE INHIBITORS | HIV | PHARMACOLOGY & PHARMACY | EXPERIENCED PATIENTS
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 03/2018, Volume 73, Issue 3, pp. 732 - 737
To determine the effect of etravirine on the pharmacokinetics of darunavir/cobicistat and vice versa. Safety and tolerability of this combination were also... 
INFECTIOUS DISEASES | MULTICENTER | EFFICACY | SAFETY | COBICISTAT | GS-9350 | MICROBIOLOGY | DARUNAVIR/RITONAVIR | DUAL THERAPY | PHARMACOLOGY & PHARMACY | EXPERIENCED PATIENTS | INHIBITOR | TREATMENT-NAIVE PATIENTS
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes
Journal Article
by Perez-Molina, J.A and Rubio, R and Rivero, A and Pasquau, J and Suárez-Lozano, I and Riera, M and Estébanez, M and Palacios, R and Sanz-Moreno, J and Troya, J and Mariño, A and Antela, A and Navarro, J and Esteban, H and Moreno, S and Pedreira Andrade, J.D and Castro Iglesias, M.A and Mena, A and López, S and Vázquez, P and Sánchez, S and Caínzos, T and Muñoz, J and Ferrero, O.L and Zubero Zulibarria, Z and Ibarra, S and Santamaría Jáuregui, J.M and Baraitzxaburu Artexe, J and Olalla, J and De Arco, A and De la Torre, J and Prada, J.L and Téllez, M.J and Vergas, J and Estada, V and Hernández Quero, J and Peña Monje, A and Parra, J and Martínez, M and Muñoz, L and Sánchez, V and Losada Arias, E and Prieto Martínez, A and Iribarren Loyarte, J.A and Ibarguren, M and Azkune Galparsoro, H and Bistinduy Odriozola, M.J and Ortiz de Barrón, X.C and Goenaga Sánchez, M.A and Von Wichmann De Miguel, M.A and Pascual Tomé, L and Camino, X and Ena, J and Pascuau, F and Amador, C and Benito, C and Barrufet, P and Force, L and Bejarano, G and Domingo Pedrol, P and Gutierren, M and Mateo, G and Terrón, A and Marín, D and Bancalero, P and Cosín, J and Berenguer, J and Miralles, P and Sánchez, M and López, J.C and Ramírez, M and Cuellar, I and Carrero, A and Portilla, J and Boix, V and Merino, E and Reus, S and Giner, L and Pampliega, M and Gutierrez, F and Masía Conto, M and Ramos Rincón, J.M and Padilla Urrea, S and Robledano García, C and Fajarso Picó, J.M and Merino Muñoz, M.D and Martínez Marcos, F.J and Rodríguez Gómez, F.J and Rayan, P and Solís, J and Palomero, N and Clotet, B and Chamorro, A and Negredo Puigmal, E and Echevarría, P and Bonjoch, A and Moltó, J and Puig, J and Ribas Blanco, M.A and Marinescu, C and ... and GeSIDA 7011 Study Grp and GeSIDA 7011 Study Group
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 2017, Volume 72, Issue 1, pp. 246 - 253
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 234 - 247
Journal Article